We are dedicated to advancing the human condition with precision bioelectric therapies that work with the body's natural electrical code.
ActiPatch® is a self-contained, FDA-cleared, over-the-counter (OTC) wearable for adjunctive treatment of musculoskeletal pain. Electrome markets and sells the device under an exclusive U.S. license from its manufacturer, BioElectronics Corporation.
Today, MATRIX Discovery, our operating internal AI-native R&D software, pairs evidence review, candidate ranking, and mathematical signal modeling with controlled laboratory validation under a human scientific release gate. It does not diagnose, monitor, or treat a person. Our FDA-cleared therapies are designed to stand alone or enhance existing care options, including traditional treatments used today.
The mat-based MATRIX System and its proposed Scan → Diagnose → Compute → Treat → Measure → Adapt → Treat again loop are future research, not capabilities available today. Diagnose is a future research goal, not an existing diagnostic capability. The System is not FDA-cleared, not an approved therapy, and not available; it would advance only through validation, human review, and an appropriate regulatory pathway.
Total Addressable Market in the U.S.
BIEL 510(k) Clearances Across ActiPatch and RecoveryRx
ActiPatch Is Sold Over the Counter in the U.S.
Our team is structured to ensure no gaps from discovery through delivery. It includes world class researchers, medical scientists, clinical advisors, product development specialists, commercialization leaders, regulatory strategists, and intellectual property experts.
Dr. Nev Zubcevik is a board-certified physician and former Harvard Medical School faculty member and Medical Director at Spaulding Rehabilitation Hospital, with deep expertise in musculoskeletal medicine, traumatic brain injury, concussion, and non-pharmacologic pain management. She is also a prolific inventor and researcher whose work spans bioelectric signaling, regenerative medicine, and chronic Lyme disease, including the LymeCure research collaboration with Tulane University, alongside peer-reviewed research on non-opioid recovery. At Electrome she directs clinical strategy, evidence generation, and the integration of bioelectric therapy into mainstream care pathways.
Erik is a physicist and entrepreneur with advanced degrees in electrical engineering and mathematics who has spent 25+ years building bioelectric recording, control, and stimulation systems, securing multiple patents, contributing to multiple successful exits, and leading work across NIST ATP, NIH, and DARPA programs. As CEO, he sets the company's strategic direction and aligns its science, technology, and commercial roadmap around a single goal, making FDA-cleared bioelectric therapy broadly accessible. He brings the rare combination of deep technical fluency and the disciplined execution and capital formation needed to build Electrome into a leader in bioelectric medicine.
Shari O'Connor is a neuroimmunology expert with 30+ years advancing brain and immune-system therapies, with board-level credentials in Neurology, Immunology, Nutrition, and Pharmacogenomics. Her published research spans encephalopathy, brain trauma, and immune-mediated neurological disease, and she has advised programs translating neuroscience research into pharmacy practice and clinical care. At Electrome she leads clinical marketing and sales development, translating the evidence base into the form clinicians, channel partners, and payer audiences evaluate and buy on. In a category where adoption is won on clinical credibility rather than promotion, her scientific standing is itself the commercial asset.
Dr. Samir S. Awad is Chief of Surgery and Operative Care Line Executive at the Michael E. DeBakey VA Medical Center in Houston, and Professor of Surgery and Vice-Chair for Surgical Quality and Safety at Baylor College of Medicine. A bioengineering graduate of Penn with surgical critical-care training at Michigan, he leads investigator-initiated clinical research across pain, wound healing, edema, and bioelectric therapeutics. At Electrome he serves as Medical Director, guiding FDA strategy and clinical evidence generation across the platform.
Wanni Davis is a biotech strategist with 15+ years spanning translational science, venture development, and commercialization. As former Director of Industry Partnerships at Harvard-affiliated hospitals, she built and negotiated the industry alliances that move academic science out of the lab and into commercial development. At Electrome she serves as Licensing Advisor, leading partnerships, business development, and alliance operations across life sciences and biopharma, including partner agreements and the licensing pathway around Electrome's patent-pending portfolio.
We create therapies that work with the body's native electrical systems, targeting the root cause, not just the symptoms, through precision bioelectric signaling.
Every therapy we develop must be grounded in rigorous science, validated by data, and deliver measurable outcomes. No hype, just evidence.
From discovery to deployment, we build technologies that scale so the right therapy can reach the right patient, at the right time, anywhere in the world.
ActiPatch is an FDA-cleared, over-the-counter (OTC), self-contained wearable for adjunctive treatment of musculoskeletal pain. It requires no app, pairing, or care-service subscription.
Drug-free, nonsystemic therapy
No app, pairing, or charging
Cleared for over-the-counter (OTC) use
Home-based delivery
We partner across sectors to bring breakthrough therapies to life, accelerating discovery, access, and real world impact through science driven collaboration. Whether you're a researcher, nonprofit, government agency, payer, or global pharma, we would love to hear from you.
Partner with us on studies, protocols, and pilot programs to advance the science of signal based healing.
Leverage our team and platform for SBIR, BARDA, NIH, and global public health initiatives.
License patented PSWT protocols or integrate our programmable platform into your portfolio, clinical or consumer.
Join our real world evidence studies using PSWT to reduce cost, risk, and drug dependency across pain and chronic care.